Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lucid Diagnostics Inc (NQ: LUCD ) 1.050 +0.050 (+5.00%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 13, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Lucid Diagnostics Inc < Previous 1 2 3 4 Next > PAVmed Digital Health Subsidiary Veris Health Launches Veris Cancer Care Platform December 15, 2022 From PAVmed Inc. Via Business Wire Lucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry December 08, 2022 From Lucid Diagnostics Inc. Via Business Wire Earnings Scheduled For May 11, 2022 May 11, 2022 Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter. Via Benzinga Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research December 01, 2022 From Lucid Diagnostics Inc. Via Business Wire PAVmed Provides Business Update and Third Quarter 2022 Financial Results November 15, 2022 From PAVmed Inc. Via Business Wire Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results November 14, 2022 From Lucid Diagnostics Inc. Via Business Wire Lucid Diagnostics Commences Production of EsoCheck Devices with High-Volume Manufacturer November 09, 2022 From Lucid Diagnostics Inc. Via Business Wire Lucid Diagnostics to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum November 10, 2022 From Lucid Diagnostics Inc. Via Business Wire Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2022 November 02, 2022 From Lucid Diagnostics Inc. Via Business Wire 12 Health Care Stocks Moving In Wednesday's Pre-Market Session August 24, 2022 Via Benzinga Lucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results August 15, 2022 From Lucid Diagnostics Inc. Via Business Wire Lucid Diagnostics Launches Stage II Lucid Test Center Expansion in California, Texas, Florida, and Ohio August 11, 2022 From Lucid Diagnostics Inc. Via Business Wire Newly Published American Gastroenterological Association Clinical Practice Update Supports Esophageal Precancer Screening Using Lucid Diagnostics’ EsoGuard® and EsoCheck® Technologies August 04, 2022 From Lucid Diagnostics Inc. Via Business Wire Lucid Diagnostics to Hold a Business Update Conference Call on August 15, 2022 August 01, 2022 From Lucid Diagnostics Inc. Via Business Wire Lucid Diagnostics’ Laboratory Executes Four New Participating Provider Agreements August 02, 2022 From Lucid Diagnostics Inc. Via Business Wire 12 Health Care Stocks Moving In Tuesday's After-Market Session July 05, 2022 Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock rose 14.5% to $0.53 during Tuesday's after-market session. The company's market cap stands at $14.0 million. Via Benzinga Lucid Diagnostics to Participate in the Canaccord 42nd Annual Growth Conference and the 7th Annual Needham Med Tech & Diagnostics 1x1 Conference July 18, 2022 From Lucid Diagnostics Inc. Via Business Wire Lucid Diagnostics Provides Business Update and Preliminary First Quarter 2022 Financial Results May 11, 2022 From Lucid Diagnostics Inc. Via Business Wire PAVmed and Lucid Diagnostics Chairman & CEO Lishan Aklog, M.D. Named Top 50 Healthcare Technology CEO May 13, 2022 From PAVmed Inc. Via Business Wire Lucid Diagnostics to Hold a Business Update Conference Call on May 11, 2022 April 25, 2022 From Lucid Diagnostics Inc. Via Business Wire Lucid Diagnostics’ Laboratory Executes Participating Provider Agreement with MediNcrease Health Plans May 09, 2022 From Lucid Diagnostics Inc. Via Business Wire How Is The Market Feeling About Lucid Diagnostics Inc. - Common Stock? March 30, 2022 Lucid Diagnostics Inc. - Common Stock's (NASDAQ:LUCD) short percent of float has fallen 4.35% since its last report. The company recently reported that it has 378.70 thousand... Via Benzinga PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results March 29, 2022 From PAVmed Inc. Via Business Wire Lucid Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinical Guideline and Proposed Medicare Local Coverage Determination April 04, 2022 From Lucid Diagnostics Inc. Via Business Wire 10 Biggest Price Target Changes For Tuesday March 29, 2022 BTIG cut the price target on NeoGenomics, Inc. (NASDAQ: NEO) from $35 to $28. NeoGenomics shares fell 29.2% to $12.60 in pre-market trading. Via Benzinga Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results March 28, 2022 From Lucid Diagnostics Inc. Via Business Wire Lucid Diagnostics to Participate in the Needham 21st Annual Healthcare Conference March 30, 2022 From Lucid Diagnostics Inc. Via Business Wire 12 Health Care Stocks Moving In Thursday's Pre-Market Session March 24, 2022 Gainers BiondVax Pharmaceuticals (NASDAQ:BVXV) shares moved upwards by 55.5% to $2.13 during Thursday's pre-market session. The market value of their outstanding... Via Benzinga PAVmed Subsidiary Lucid Diagnostics Announces Launch of VA EsoGuard® Study March 24, 2022 From Lucid Diagnostics Inc. Via Business Wire PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers March 23, 2022 From Lucid Diagnostics Inc. Via Business Wire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
